Meeting
2021 ASCO Annual Meeting
Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.
Authors
Katherine B. Peters
Duke University, Durham, NC
Katherine B. Peters , John L. Villano , Nicholas A. Butowski , Adam Louis Cohen , Joe Sammy Mendez , Pierre Giglio , Chi Zhang , Shahzad Raza , Tresa McGranahan , Mina Lobbous , David MacLeod , Shayne Gad , Sara Penchev , David Silberstein , James Crapo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT02655601
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS2069)
DOI
10.1200/JCO.2021.39.15_suppl.TPS2069
Abstract #
TPS2069
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
First Author: Manmeet Singh Ahluwalia
Poster
2022 ASCO Annual Meeting
Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.
First Author: Ina Ly
Poster
2019 ASCO Annual Meeting
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
First Author: Hao-Wen Sim
Poster
2018 ASCO Annual Meeting
A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility and safety outcomes (the VERTU study).
First Author: Mustafa Khasraw